Development

Meg Rivers is the former senior editor for 

Articles

New technologies are treatments are emerging to tackle COVID-19 and its assortment of new variants.

The Next Step For COVID-19 Vaccines

Jennifer Markarian is manufacturing editor of BioPharm International.

Flexible and efficient methods are needed for biopharmaceutical manufacturing. 

Demonstrating a Fully Continuous Bioprocess

Editor of Pharmaceutical Technology Europe

Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.

Method Development in Demand

Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.

Evolving Demands of Process Development Services

Although mRNA and viral vector vaccines have been top of mind for COVID-19 treatments, other technologies and treatments are emerging—along with new variants. 

What’s Next for COVID-19 Vaccines and Variants? 

Prashant Pokhriyal is associate scientist at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Prateek Gupta is senior general manager at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Sridevi Khambhampaty is vice-president at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Rajesh Ullanat is executive vice-president at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Mili Pathak is principal scientist, Process Science, R&D, at Intas Pharmaceuticals Ltd. (Biopharma Division), Ahmedabad, Gujarat, India.

Modeling techniques can improve process control and monitoring in biopharmaceutical production.

Recent Trends in Data Analytics for Upstream Process Workflows

Toni Manzano, toni.manzano@aizon.ai, is chief science officer and co-founder at Aizon.

Qualified algorithms enable validation of machine learning models that can be used for process optimization. 

Qualifying AI Algorithms in Pharmaceutical Manufacturing

Genezen has opened its new process development and analytical lab for viral vector production.

Genezen Starts Up Operations at Lenti- and Retroviral Vector Process Development Lab

Feliza Mirasol is the science editor for 

Chris Spivey is the editorial director of 

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2

Ajinomoto and its subsidiary company, Ajinomoto Genexine, have partnered with Insilico Biotechnology to accelerate and improve process development and production of biologics using digital twin technology.